Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000391

Drug Information
NameTrastuzumab    
SynonymsTrastuzumab (genetical recombination) (JAN); Herceptin (TN); Trastuzumab; 180288-69-1; Herceptin; D03257; Trastuzumab (INN); Trastuzumab (genetical recombination)    
Trade NameHerceptin    
CompanyRoche & Genentech    
IndicationBreast cancerApproved    [1]
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 180288-69-1
FormularC6470H10012N1726O2013S42    
PubChem Substance IDSID 17397410.    
SuperDrug ATC IDL01XC03;    
SuperDrug CAS ID180288691;    
TargetReceptor protein-tyrosine kinase erbB-2Antibody[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. To Reference
Ref 3Nat Rev Drug Discov. 2003 Jan;2(1):38-51.Knockouts model the 100 best-selling drugs--will they model the next 100? To Reference
Ref 4Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother. 2002 Jan;50(11):569-87. Epub 2001 Nov 24. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543